The Pax-5 gene: A pluripotent regulator of B-cell differentiation and cancer disease

Cancer Research

Volumn 71, Issue 24, 2011, Pages 7345-7350

  O'Brien, Pierre ^a,b   Morin Jr , Pier ^a   Ouellette, Rodney J ^a,b   Robichaud, Gilles A ^a,b  

^a UNIVERSITÉ DE MONCTON   (Canada)

^b ATLANTIC CANCER RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DAXX PROTEIN; FIBRONECTIN; GELATINASE A; HISTONE ACETYLTRANSFERASE; JANUS KINASE 2; METASTASIS ASSOCIATED PROTEIN 1; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; STAT5 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; VIMENTIN;

ACETYLATION; B CELL LYMPHOMA; B LYMPHOCYTE DIFFERENTIATION; CARCINOGENESIS; CELL FATE; CELL GROWTH; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; GENE ACTIVATION; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE PRODUCT; GENETIC REGULATION; HUMAN; LYMPHATIC LEUKEMIA; LYMPHOPOIESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; NONHUMAN; ONCOGENE; PAX5 GENE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MODELS, GENETIC;

EID: 84255170476     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1874     Document Type: Review

References (38)

1. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol 2004;22:55-79. (Pubitemid 38680418)
2. Robson EJ, He SJ, Eccles MRA. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006;6:52-62. (Pubitemid 43053651)
3. Decker T, Pasca di Magliano M, McManus S, Sun Q, Bonifer C, Tagoh H, et al. Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis. Immunity 2009;30:508-20.
4. Holmes ML, Pridans C, Nutt SL. The regulation of the B-cell gene expression programme by Pax5. Immunol Cell Biol 2008;86:47-53.
5. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 2006;24:269-81.
6. Pfeffer PL, Bouchard M, Busslinger M. Pax2 and homeodomain proteins cooperatively regulate a 435 bp enhancer of the mouse Pax5 gene at the midbrain-hindbrain boundary. Development 2000;127:1017-28. (Pubitemid 30162648)
7. Robichaud GA, Nardini M, Laflamme M, Cuperlovic-Culf M, Ouellette RJ. Human Pax-5 C-terminal isoforms possess distinct transactivation properties and are differentially modulated in normal and malignant B cells. J Biol Chem 2004;279:49956-63. (Pubitemid 39577804)
8. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998;92:1308-16. (Pubitemid 28369044)
9. Poppe B, De Paepe P, Michaux L, Dastugue N, Bastard C, Herens C, et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 2005;44:218-23. (Pubitemid 41306651)
10. Souabni A, Jochum W, Busslinger M. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus. Blood 2007;109:281-9. (Pubitemid 46053068)
11. Cozma D, Yu D, Hodawadekar S, Azvolinsky A, Grande S, Tobias JW, et al. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest 2007;117:2602-10. (Pubitemid 47494361)
12. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 2001;61:4666-70. (Pubitemid 32691872)
13. Nebral K, König M, Harder L, Siebert R, Haas OA, Strehl S. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. Br J Haematol 2007;139:269-74. (Pubitemid 47493075)
14. Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 2008;68:181-9. (Pubitemid 351380119)
15. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758-64. (Pubitemid 46582031)
16. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007;449:473-7. (Pubitemid 47509547)
17. Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med 2011;208:1135-49.
18. Vidal LJ, Perry JK, Vouyovitch CM, Pandey V, Brunet-Dunand SE, Mertani HC, et al. PAX5alpha enhances the epithelial behavior of human mammary carcinoma cells. Mol Cancer Res 2010;8:444-56.
19. Vouyovitch CM, Vidal L, Borges S, Raccurt M, Arnould C, Chiesa J, et al. Proteomic analysis of autocrine/paracrine effects of human growth hormone in human mammary carcinoma cells. Adv Exp Med Biol 2008;617:493-500.
20. Crapoulet N, O'Brien P, Ouellette RJ, Robichaud GA. Coordinated expression of Pax-5 and FAK1 in metastasis. Anticancer Agents Med Chem 2011;11:643-9.
21. Baumann Kubetzko FB, Di Paolo C, Maag C, Meier R, Schäfer BW, Betts DR, et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 2004;25:1839-46. (Pubitemid 39405902)
22. Robichaud GA, Perreault JP, Ouellette RJ. Development of an isoform-specific gene suppression system: the study of the human Pax-5B transcriptional element. Nucleic Acids Res 2008;36:4609-20.
23. Lowen M, Scott G, Zwollo P. Functional analyses of two alternative isoforms of the transcription factor Pax-5. J Biol Chem 2001;276:42565-74.
24. Proulx M, Cayer MP, Drouin M, Laroche A, Jung D. Overexpression of PAX5 induces apoptosis in multiple myeloma cells. Int J Hematol 2010;92:451-62.
25. Liu W, Li X, Chu ES, Go MY, Xu L, Zhao G, et al. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology 2011;53:843-53.
26. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009;89:301-14.
27. Ellsworth RE, Seebach J, Field LA, Heckman C, Kane J, Hooke JA, et al. A gene expression signature that defines breast cancer metastases. Clin Exp Metastasis 2009;26:205-13.
28. Balasenthil S, Gururaj AE, Talukder AH, Bagheri-Yarmand R, Arrington T, Haas BJ, et al. Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res 2007;67:7132-8. (Pubitemid 47206540)
29. Hirokawa S, Sato H, Kato I, Kudo A. EBF-regulating Pax5 transcription is enhanced by STAT5 in the early stage of B cells. Eur J Immunol 2003;33:1824-9. (Pubitemid 37120853)
30. Fitzsimmons D, Lukin K, Lutz R, Garvie CW, Wolberger C, Hagman J. Highly cooperative recruitment of Ets-1 and release of autoinhibition by Pax5. J Mol Biol 2009;392:452-64.
31. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003;2:29.
32. Emelyanov AV, Kovac CR, Sepulveda MA, Birshtein BK. The interaction of Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells. J Biol Chem 2002;277:11156-64. (Pubitemid 34952877)
33. Eberhard D, Busslinger M. The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins. Cancer Res 1999;59 (7 Suppl):1716s-24s; discussion 24s-5s.
34. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995;14:5638-45.
35. Bougel S, Renaud S, Braunschweig R, Loukinov D, Morse HC 3rd, Bosman FT, et al. PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. J Pathol 2010;220:87-96.
36. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 2007;27:49-63. (Pubitemid 47096800)
37. Pridans C, Holmes ML, Polli M, Wettenhall JM, Dakic A, Corcoran LM, et al. Identification of Pax5 target genes in early B cell differentiation. J Immunol 2008;180:1719-28.
38. Walter K, Cockerill PN, Barlow R, Clarke D, Hoogenkamp M, Follows GA, et al. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5. Oncogene 2010;29:2927-37.